Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Neothetics Inc.
DescriptionSubcutaneous formulation of salmeterol xinafoate, a long-acting adrenergic receptor beta 2 agonist (LABA)
Molecular Target Adrenergic receptor beta 2 (ADRB2)
Mechanism of ActionAdrenergic receptor beta 2 (ADRB2) agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationBody Fat
Indication DetailsReduce subcutaneous abdominal fat
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today